PIPSL

Across TCGA pan-cancer cohorts, PIPSL Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated PIPSL data layer compared with 23 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher PIPSL Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated PIPSL expression acts as an unfavorable survival marker, although some lineages such as COAD show a favorable association.

LUAD, DLBC, and SARC are the cancer types where PIPSL Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	All	0.183	0.658	.001	33	view →
DLBC	DFS	Median	II,III,IV	0.065	0.829	<.001	24	view →
SARC	OS	Median	All	0.016	0.861	<.001	12	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
HNSC	DFS	Median	III,IV	0.143	0.682	<.001	6	view →
COAD	DFS	Median	II,III,IV	1.000	0.417	.020	4	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

PIPSL–LUAD (DFS)

Open the LUAD breakdown →